Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
In a two-part series, this first paper outlines the quality and regulatory thinking that underpins RBQM, and details essential points of compliance for emerging ICH core guidances on RBQM—including ICH E8 (R1) and ICH GCP E6 (R3)—and offers further discussion of RBQM implications for sponsors, clinical sites and patients.n a two-part series, this first paper outlines the quality and regulatory thinking that underpins RBQM, and details essential points of compliance for emerging ICH core guidances on RBQM—including ICH E8 (R1) and ICH GCP E6 (R3)—and offers further discussion of RBQM implications for sponsors, clinical sites and patients. n a two-part series, this first paper outlines the quality and regulatory thinking that underpins RBQM, and details essential points of compliance for emerging ICH core guidances on RBQM—including ICH E8 (R1) and ICH GCP E6 (R3)—and offers further discussion of RBQM implications for sponsors, clinical sites and patients.
Related Insights
Webinar
Global trial expansion: Navigating Australia & LATAM's evolving clinical research landscape
Dec 2, 2025
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Video
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026
Related Insights
Webinar
Global trial expansion: Navigating Australia & LATAM's evolving clinical research landscape
Dec 2, 2025
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Video
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026